Cargando…

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience

BACKGROUND: Isavuconazole (ISA) is an attractive candidate for prophylaxis against invasive mould infections (IMIs) due to its broad-spectrum activity, ease of dosing, favorable side-effect profile, and limited drug–drug interactions. Clinical experience using ISA prophylaxis in high-risk patients i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontana, Lauren, Lewis II, James S, Hakki, Morgan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255608/ http://dx.doi.org/10.1093/ofid/ofy210.371

Ejemplares similares

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

2709. Breakthrough fungal infection after isavuconazole primary prophylaxis in patients with hematologic malignancy and hematopoietic stem cell transplant: Systematic Review
por: Ishida, Keiko, et al.
Publicado: (2023)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Pseudomonas aeruginosa ExoU-associated virulence in HCT recipients and patients with hematologic malignancies
por: Fontana, Lauren, et al.
Publicado: (2023)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

2278. Emergence of Resistance and Associated Mortality during Persistent Pseudomonas aeruginosa Bacteremia in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients
por: Fontana, Lauren, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

2106. Evaluation of Isavuconazole for the Prophylaxis and Treatment of Invasive Fungal Infections at a Large Academic Medical Center
por: Vu, Christine, et al.
Publicado: (2019)

Successful treatment of Trichosporon asahii fungemia with isavuconazole in a patient with hematologic malignancies
por: Feugray, Guillaume, et al.
Publicado: (2019)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience
por: Salas, Maria Queralt, et al.
Publicado: (2022)

Inhaled Amphotericin B as Aspergillosis Prophylaxis in Hematologic Disease: An Update
por: Duckwall, Madison J, et al.
Publicado: (2019)

355. Invasive Pulmonary Aspergillosis (IPA) Complicating Respiratory Viral Infections in Patients With Hematological Malignancies
por: Magira, Eleni, et al.
Publicado: (2018)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
por: Miller, Michelle, et al.
Publicado: (2022)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Isavuconazole for invasive fungal infections
Publicado: (2020)

Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: Dagher, Hiba, et al.
Publicado: (2022)

Prognosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases in Korea
por: Kwon, Jae-Cheol, et al.
Publicado: (2012)

Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus
por: Al-Obaidi, Mohanad, et al.
Publicado: (2018)

Comparing Diagnostic-Driven Approaches to Empiric Therapy in the Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancy
por: Dib, Rita Wilson, et al.
Publicado: (2017)

Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies
por: Dib, Rita Wilson, et al.
Publicado: (2018)

Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia
por: Tolnai, Emese, et al.
Publicado: (2020)

Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
por: Chien, Kelly S., et al.
Publicado: (2023)

272. Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy vs. Solid Tumor
por: Wilson Dib, Rita, et al.
Publicado: (2019)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

1182. The Real-World Use of Isavuconazole as Primary or salvage Therapy of Invasive Fungal infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: dagher, Hiba, et al.
Publicado: (2020)

Emergence of non-susceptibility during persistent Pseudomonas aeruginosa bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients
por: Fontana, Lauren, et al.
Publicado: (2021)

Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
por: Kronig, Ilona, et al.
Publicado: (2021)

Comparative evaluation of galactomannan test with bronchoalveolar lavage and serum for the diagnosis of invasive aspergillosis in patients with hematological malignancies
por: Gupta, Ankit, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0vnop99j8g1uqhcgie3qac49p3